drugset / Trial / NCT07277179

Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis

NCT07277179

Phase 3 Completed 113 enrolled SPH-BIOCAD (HK) Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with Active Ankylosing Spondylitis. Researchers will compare Netakimab to placebo to see if Netakimab works to treat Ankylosing Spondylitis.

Timeline

Start
2023-03-20
Primary completion
2024-07-05
Completion
2025-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Netakimab Monoclonal antibody Subcutaneous